ERBB2 and breast carcinoma: These studies also showed that gefitinib in combination with HCQ engendered tumor growth inhibition in mice bearing subcutaneous HER2-overexpressing gefitinib-resistant JIMT-1 breast cancer tumor xenografts to a greater extent than either drug alone [7].